Loading...
•
Jun 30, 2024
Janux Q2 2024 Earnings Report
Janux reported financial results for the second quarter of 2024 and provided a business update.
Key Takeaways
Janux Therapeutics reported a net loss of $6.0 million for the second quarter of 2024. The company's cash and cash equivalents and short-term investments totaled $646.3 million as of June 30, 2024. They also received a $7.5 million milestone payment from Merck.
Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors.
An update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024.
Eric Dobmeier and Natasha Hernday were appointed to the Board of Directors.
The company received a $7.5 million development milestone payment from Merck.
Revenue by Segment
Forward Guidance
Janux anticipates providing an update on JANX007 data and doses selected for expansion cohorts in 2H 2024. An update on JANX008 data is expected in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...